Highlights Pfizer Inc.

Stocks

PFE

US7170811035

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 04:05:24 2026-06-15 pm EDT			5-day change	1st Jan Change
26.06 ^USD	-0.55%		+1.89%	+4.84%

06:56am	Global drugmakers invest billions to boost US presence	RE
Jun. 12	Drugmakers will not be exempt from cost cuts, says German health minister	RE

Highlights

Jun. 11	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Jun. 11	Commission's appeal against COVID vaccine contract disclosures should be dismissed, court adviser says	RE
Jun. 08	U.S. FDA Approves Pfizer?s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need	CI
Jun. 08	US FDA approves Pfizer's bleeding disorder drug for children	RE
Jun. 06	Pfizer Presents Detailed Results From Multiple Phase 2b Studies Of Berobenatide And Plans To Advance 10 Phase 3 Studies For Chronic Weight Management And Obesity-Related Comorbidities	CI
May. 31	Pfizer Inc. Announces Detailed Progression-Free and Overall Survival Results from Cohort 3	CI
May. 30	Pfizer Inc. Announces detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA	CI
May. 29	Pfizer Inc. Reports Seven-Year Follow-Up Results From The CROWN Trial Evaluating LORBRENA Versus XALKORI In ALK-Positive Advanced Or Metastatic Non-Small Cell Lung Cancer	CI
May. 29	Pfizer says EC authorizes update to pediatric use of Pfizer & BioNTech Covid 19 vaccine	RE
May. 29	Pfizer, Innovent Biologics Strike Cancer Drug Partnership Worth up to $10.5 Billion	MT
May. 28	Innovent Biologics, Pfizer strike $10.5 bln cancer drug deal amid China biotech boom	RE
May. 20	Sarah Cannon Research Institute and Pfizer Announce Strategic Oncology Research Collaboration	CI
May. 20	Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial	RE
May. 20	Pfizer Inc Advances Pivotal Pediatric Pneumococcal Vaccine Program	CI
May. 13	Pfizer Inc Approves Hympavzi for Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors	CI
May. 13	European Commission approves Pfizer's Hympavzi for the treatment of adults and adolescents with hemophilia A or B with inhibitors	RE
May. 13	Pfizer Says European Commission Approves Expanded Indication for Hympavzi	MT
May. 07		FA
May. 05	Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC	MT
May. 05	Health Care Up After Earnings - Health Care Roundup	DJ
May. 05	Pfizer Tops First-Quarter Estimates, Reaffirms Full-Year Outlook	MT
May. 05	Pfizer Inc. Reports Earnings Results for the First Quarter Ended March 29, 2026	CI
May. 05	Pfizer Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 05	Pfizer 1Q Revenue Rises But Profit Falls Amid Boosted R&D Spending	DJ
May. 05	Pfizer Q1 Adjusted Earnings Fall, Revenue Rises	MT